tislelizumab + cisplatin + gemcitabine + trilaciclib + dehydroepiandrosterone

This entry represents a composite of two distinct clinical trial regimens identified from the provided name and context. The first component is an oncology combination therapy consisting of **tislelizumab** (a PD-1 checkpoint inhibitor), **trilaciclib** (a CDK4/6 inhibitor), and the chemotherapy agents **cisplatin** and **gemcitabine**. This regimen has been evaluated in Phase 2 clinical trials (e.g., NCT04863248) for the treatment of metastatic urothelial carcinoma and bladder cancer to improve antitumor response while mitigating chemotherapy-induced myelosuppression. The second component, specifically associated with Bayer in the provided context, is **dehydroepiandrosterone (DHEA)**, also known as prasterone. Bayer evaluated a 100 mg daily oral dose of DHEA in a Phase 2 study (NCT03321825) as an add-on to oral contraceptives to treat hypoactive sexual desire disorder (HSDD) or reduced libido in women. DHEA acts as an endogenous pro-hormone that is converted into active androgens and estrogens, and also functions as a neurosteroid to modulate sexual desire and arousal.

Other names

prasteroneDHEA3β-hydroxyandrost-5-en-17-one